XXXX in Adenoid Hypertrophy: Its Effect on Size and Symptoms.

@entity1 @entity548 @entity1353 @entity1184 @entity27 @entity4352 @entity5203 @entity6954 @entity65
INTRODUCTION: @entity1184 ( @entity1184 ) is considered the most common cause of upper respiratory tract obstruction among @entity1 . It results in a spectrum of symptoms from mouth @entity1353 , nasal obstruction, hyponasal speech, snoring, and @entity27 ( @entity27 ) to growth failure and @entity65 . Adenotonsillectomy is a typical strategy for @entity1 with @entity1184 , but may lead to serious complications such as @entity548 (4-5%) and postoperative respiratory compromise (27%), especially among young @entity1 , as well as recurrence of adenoid tissue (10-20%). Thus, non-surgical therapies have attracted considerable attention as an alternative strategy. The inflammatory mechanism proposed for @entity1184 has lead to the use of anti-inflammatory drugs to manage this condition. The present study aimed to evaluate the effect of chewable tablets of @entity5203 , a @entity6954 - @entity4352 receptor antagonist, in @entity1 with @entity1184 . MATERIALS AND METHODS: Sixty @entity1 between the ages of 4-12 years with >75% choanal obstruction on primary nasal endoscopy were recruited in this randomized, placebo-controlled trial and randomly divided into two groups. The study group was treated with @entity5203 5 mg daily for 12 weeks while the control group received matching placebo for the same period of time. A questionnaire was completed by each @entity1 's parent/guardian to assess the severity of sleep discomfort, snoring, and mouth @entity1353 before and after the intervention. RESULTS: Adenoid size decreased in 76% of the study group compared with 3% of the placebo group after 12 weeks. A statically significant improvement was observed in the study group compared with the placebo group in terms of sleep discomfort, snoring, and mouth @entity1353 . The symptoms average total score dropped from 7.7 to 3.3 in the study group, while in the placebo group the total score changed from 7.4 to 6.7. CONCLUSION: @entity5203 chewable tablets achieved a significant reduction in adenoid size and improved the related clinical symptoms of @entity1184 and can therefore be considered an effective alternative to surgical treatment in @entity1 with @entity1184 .
